53 results about "Pneumonocyte" patented technology

The invention provides methods for analyzing and predicting the in vivo respiratory toxicity of a compound (e.g., pharmaceutical, biological, cosmetic, or chemical compounds) or composition comprising a combination of an in vitro mammalian cell model with multiple endpoint analysis, and time and concentration response curves. The methods allow the determination of a predicted in vivo respiratory toxicity value of a compound without the use of animals, with a high degree of accuracy. The methods comprise detecting any combination of cell viability markers and expression levels of genes implicated in respiratory toxicity and / or sensitization, such as pro-inflammatory response genes, combining the viability and gene expression level data with concentration response and time response data, conducting a computational analysis, and comparing test compound data to a database of known respiratory toxicants / sensitizers to predict and / or analyze the respiratory toxicity. An indication of organ specificity is provided by a toxicity index, which is determined by comparing mean IC50 values in lung cells to mean IC50 values in liver cells.

The present invention relates to methods and compositions for importing DNA into the nuclei of a specific cell type. In particular, the present invention provides methods and compositions for specifically targeting the nuclei of pulmonary cells.

A novel targeting peptide from the C-terminal of endothelin and / or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase genes, particularly, the human serum butyryl cholinesterase (Hu BChE) gene, as a treatment against nerve agents. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b).

The invention discloses a medicine for treating lung cancer and a preparation method thereof, and the medicine is prepared by 23 medicines such as bittersweet herb, solanum nigrum, radix astragali, bighead atractylodes rhizome, indian bread, dried orange peel, almond, radix stemonae, heartleaf houttuynia herb, Chinese sage herb, herb selaginellae doederleinii, Chinese pearl barley, roasted tatarian aster root, fructus psoraleae, etc. The preparation method is that the 23 medicines are soaked by 10 times of water for 120 minutes, the medicines together with the water firstly are decocted for 15-20 minutes to the temperature of 100 DEG C by high heat, and then are decocted for 40-50 minutes by slow fire to be cooled bellow 40 DEG C for extracting juice, removing slag and clarification; clear solution is taken to be concentrated by two third to be prepared into ointment, or the clear solution is put into a drying cabinet with the temperature of 80-90 DEG C to be dried for 8-9 hours, and then the clear solution is taken out to be prepared into pulvis, medicinal granules or pills after drying. The medicine has strong penetrability, can quickly permeate into cancer cell, can effectively prevent the catastrophe, shift and spread of the cancer cell, and has restoration effects on pneumonocyte without toxic and side effect.

The vasculature of a donor lung is perfused with a lung preserving fluid to preserve its structure. At the same time, a decellularization fluid is perfused through the airways, which strips away donor cells. The decellularized region is then seeded with pulmonary cells of the transplant recipient, which regenerate the lung. The pulmonary cells may be derived from stem cells, and the decellularization can be targeted to reduce the quantity of cells required.

A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.

A novel targeting peptide from the C-terminal of endothelin and / or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase genes, particularly, the human serum butyryl cholinesterase (Hu BChE) gene, as a treatment against nerve agents. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b).

This disclosure is directed to methods, compounds and compositions for delivering nucleic acids to a cell of interest. In particular, it provides salts that are particularly effective in delivering nucleic acids to cells in the lung for disorders such as cystic fibrosis (CF).

The invention relates to a human recombination gene lung epithelial cell, in particular to a human lung cell BEAS-2B / CYP2A13 and application thereof. The human lung cell BEAS-2B / CYP2A13 is characterized in that: the cell strain is collected in China Center for Type Culture Collection, and the collection number is CCTCC No: C2010127. In the method, the BEAS-2B cell for stably expressing CYP2A13 is constructed by utilizing a slow virus system for the first time at home and abroad, which is the key technology in the invention. Compared with other virus vector systems, the technology has the advantages of high transfection efficiency, stable expression, easiness in screening and the like, and has the unique advantage on transfection of immortalized cells.

Stem cells are induced in culture to form cells which express surfactant protein C (SPC), thereby offering a convenient and abundant supply of alveolar tissue without requiring lung donation or the use of cadavers. Stem cells are cultured to give embryoid bodies, which are they maintained under conditions which cause them to differentiate into cells which express SPC. SAGM medium has been found to be particularly effective for causing differentiation of the embryoid bodies.

The invention discloses a method for extracting polypeptide through tadpole enzymolysis and the polypeptide prepared by the method. According to the extraction method disclosed by the invention, an immobilized nano-enzyme technology is adopted, a mixture of Alcalase protease and bromelain is used, and a tadpole enzymolysis polypeptide extract with oxidation resisting activity and the polypeptide with the amino acid sequence of Glu-Trp-Ala-Pro-Pro-Ser-Lys-Leu-Leu-Leu-Lys are obtained, play a role in protecting type II pneumonocyte and can be used for preventing and / or treating lung injury.

The invention discloses a pharmaceutical composition as well as a preparation method and application thereof. In the application, the pharmaceutical composition comprises CD31- and CD73-positive mesenchymal stem cells and / or exosomes thereof, has functions of inhibiting inflammatory cytokine secretion, promoting lung regeneration cytokine secretion, inhibiting pulmonary fibrosis, preventing pulmonary cell apoptosis and the like, and can prevent or treat pulmonary degenerative diseases including chronic obstructive pulmonary disease (COPD).

The invention discloses an application of ferulic acid in the preparation of a medicine for preventing and treating lung inflammation. A new possible medicine is provided for preventing and treating inflammatory injury suffered by lungs, and a certain experimental basis is provided for development and function research of natural polyphenol compound resources. The ferulic acid can be used for preventing and treating lung cell injury caused by chromium pollution, assembling NLRP3 inflammatory corpuscles and expressing cell inflammatory factors so as to play a protective role. Ferulic acid is aphenolic compound, has a wide plant source, exists in rice, apples, peanuts and coffee, has various biological activities and has potential of deep development.

The invention provides an in-vitro detection method for forms of micro-elements in metal concentrate, which specifically comprises the following steps: respectively measuring the contents of the micro-elements in the concentrate by adopting an X-ray fluorescence spectrophotometer; according to the measured content of the microelements in the concentrate, preparing a to-be-measured liquid of the microelements; respectively culturing the lung cell line and the stomach cell line in a container which is divided into a top side chamber and a substrate side chamber by a porous membrane; respectively adding the micro-element liquid to be detected into the lung cell line and the stomach cell line, and culturing the whole container in an incubator for 24 hours; collecting samples of the lung cell line and the stomach cell line; respectively measuring the contents of the micro elements of the lung cell line by using inductively coupled plasma mass spectrometry; and respectively determining the contents of different forms of the microelements by using a high performance liquid chromatography and inductively coupled plasma mass spectrometry combined method. According to the method provided by the invention, the content of the micro elements in the metal concentrate in the specific tissues of the human body can be accurately detected, and different forms of the micro elements can be analyzed, so that the damage to the human body can be more accurately evaluated.

The invention belongs to the technical field of biological medicine, and provides a colorectum-targeted drug-loaded exosome and application thereof, and a medicine for treating colorectal diseases. The colorectum-targeted drug-loaded exosome is obtained by introducing the medicine for treating the colorectal diseases into an exosome with a colorectal tissue targeting property; and the exosome with colorectal tissue targeting property is derived from lung cells. A colorectal tumor treatment drug contains the colorectum-targeted drug-loading exosome. Compared with the prior art, the exosome secreted by the lung cells can be enriched in the colorectum without any modification, the exosome derived from the lung cells is used, the problem of exosome yield is solved, and good application prospect is obtained; and different drugs or active molecules can be loaded by using the lung cell-derived exosome, and the treatment effect of colorectal diseases is improved and toxic and side effects of the drugs are reduced through targeted colorectal tissue administration.

The invention provides application of an exosome derived from mesenchymal stem cells in preparation of a medicine for treating acute lung injury caused by sulfur mustard. The invention particularly relates to separation of bone marrow mesenchymal stem cell supernate to obtain exosomes and application of the exosomes to acute lung injury caused by sulfur mustard. The exosomes can significantly improve survival rate of experimental animals and improve activity of lung cells under the exposure of sulfur mustard, improves changes in lung tight junction proteins caused by sulfur mustard, and resists lung injury effect of sulfur mustard. Therefore, the invention provides a new treatment approach for acute lung injury caused by sulfur mustard.

The present disclosure relates to a pharmaceutical composition for preventing or treating an inflammatory respiratory disease, which contains a fusion protein in which a cell-penetrating peptide and a ctCTLA4 peptide are fused as an active ingredient. The present disclosure can provide quick, fast, and effective therapeutic or preventive effect for inflammatory respiratory diseases, particularly allergic asthma, via administration through the respiratory system, with which effective therapeutic or preventive effect could not be achieved, by providing superior delivery and targeting efficiency for a bronchus and lung cells and remarkably improved activities of suppressing cytokine expression, suppressing airway inflammation, alleviating airway hyperresponsiveness to allergens, alleviating Th2 inflammation, etc. as compared to the existing therapeutic agents.

The invention belongs to the technical field of biological medicines, and discloses application of intervening BOK in preparation of a medicine for treating novel coronavirus pneumonia. In order to find a new immunotherapy scheme for comprehensive treatment of novel coronavirus pneumonia, the research on the lung tissue of novel coronavirus pneumonia patients finds that the expression quantity of BOK in the lung tissue cell of the novel coronavirus pneumonia patients is increased, BOK gene knockout can inhibit the apoptosis of human lung cells and vascular endothelial cells induced by a novel coronavirus membrane protein, and BOK knockdown by injecting lentivirus into the trachea of a mouse to express shRNA (short hairpin Ribonucleic Acid) aiming at BOK can inhibit the apoptosis of the lung tissue induced by the novel coronavirus membrane protein, which indicates that BOK is expected to be applied to the comprehensive treatment of the novel coronavirus pneumonia and is prepared into the form of a medicine for treating the novel coronavirus pneumonia, which can relieve lung injury and alveolar cavity fluid infiltration of the novel coronavirus pneumonia patients, and is suitable for protecting lung tissues and organs in the novel coronavirus pneumonia process.

The present invention is a method for manufacturing an animal model for researching a pulmonary tumor and a use thereof. A transgenic non-human animal of the present invention is prepared by embryonic gene microinjection and possesses a tissue-specific expression of vascular endothelial growth factor A165 (VEGF-A165) in lung. Through the expression of vascular endothelial growth factor A165, the lung cells in the transgenic non-human animal of the present invention have inflammatory, vascularogenesis and angiogenesis responses or induce lung tumors. Thus, the non-human animal of the present invention can serve as an animal model for analyzing the regulation and the anti-tumor drugs screening of pulmonary adenocarcinoma.

The invention provides a method for culturing lung tumor organoids, and belongs to the field of organoid culture. The invention firstly provides a lung tumor organoid culture container which is a cell culture container with a lung extracellular matrix imprinting block array on the bottom surface in the lung tumor organoid culture container; the area, not covered with the lung extracellular matrix, of the bottom surface is sealed by a sealing agent; the lung extracellular matrix imprinting block array is composed of circular array points with the diameter of 50-200 [mu] m, and the distance between every two circular array points is 25-300 [mu] m. The invention further provides a culture method of the lung tumor organoid, the culture time is shortened, the culture mode is simplified, the particle size and arrangement of the lung tumor organoid are effectively controlled, and the repeatability and stability of drug screening are improved. The cultured lung tumor organoid is used for drug screening, higher efficiency and safety are achieved, meanwhile, personalized treatment can be conducted, and clinical medication is guided.

The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell, and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.

Vesicles, including exosomes, having a coating of a hydrophilic, neutral polymer such as PEG have an increased ability to form a suspension or colloid compared to uncoated vesicles. This enables the coated vesicles to be used to form aerosol droplets such that a liquid formulation containing vesicles can be used in a nebulizer for inhaled administration thereof. Such coated vesicles are also able to pass through mucus and can deliver their cargo into lung cells. Exosomes from mesenchymal stem cells can deliver additional proteins, miRs, mRNAs and other nucleic acid sequences to lung cells providing a regenerative gene therapy for CF, COPD lung cancer and other lung diseases.

The invention discloses a BeSO4 contaminated rat lung tissue differential expression protein detection and analysis method. The method comprises the following steps: 1, obtaining rat lung tissues; 2, preparing a sample; 3, carrying out protein reduction treatment; 4, performing protein alkylation treatment; 5, carrying out proteolysis; 6, carrying out TMT labeling on the protein; 7, performing LC-MS / MS detection on the sample; 8, carrying out enrichment analysis on GO and KEGG; and 9, carrying out PPI network diagram analysis. According to the invention, by using a TMT-labeled quantitative proteomics technology and a bioinformatics analysis technology, the protein expression condition of the BeSO4 contaminated rat lung tissue is rapidly detected in a high-throughput mode, and key protein is rapidly and accurately screened out of the rat lung tissue, so that the research direction is pointed out for the occurrence mechanism of the BeSO4-induced lung cell injury, and the important guiding significance is achieved for diagnosis and treatment of the beryllium lung.